Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling.

Epidermal growth factor receptor (EGFR) has been recognized as one of the attractive targets for anticancer drug development. Herein, a set of anilino-1,4-naphthoquinone derivatives () was synthesized and investigated for their anticancer and EGFR inhibitory potentials. Among all tested compounds, three derivatives (, , and ) were selected for studying EGFR inhibitory activity ( and ) due to their most potent cytotoxic activities against six tested cancer cell lines (i.e., HuCCA-1, HepG2, A549, MOLT-3, MDA-MB-231, and T47D; IC values = 1.75-27.91 μM), high selectivity index (>20), and good predicted drug-like properties. The experimental results showed that these three promising compounds are potent EGFR inhibitors with nanomolar IC values (3.96-18.64 nM). Interestingly, the most potent compound bearing 4-methyl substituent on the phenyl ring displayed 4-fold higher potency than the known EGFR inhibitor, erlotinib. Molecular docking, molecular dynamics simulation, and MM/GBSA-based free energy calculation revealed that van der Waals force played a major role in the accommodations of compound within the ATP-binding pocket of EGFR. Additionally, the 4-CH moiety of the compound was noted to be a key chemical feature contributing to the highly potent EGFR inhibitory activity its formations of alkyl interactions with A743, K745, M766, and L788 residues as well as additional interactions with M766 and T790.